Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Vulvar Neoplasms 2Melanoma 2Liver Metastases 2Breast Neoplasms 2Ulcer 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Pathologic Processes 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Liver Neoplasms 1Head and Neck Neoplasms 1Gynecological Cancers 1Colorectal Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × Electrochemotherapy × Clear all
NCT07404605 2026-02-19

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

Institute of Oncology Ljubljana

Phase NA Recruiting
150 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

European Institute of Oncology

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡